Efgartigimod
High EvidenceEfgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis.
What It Is
Efgartigimod is the drug that turned a housekeeping receptor into a therapeutic target. Almost every antibody drug and every natural antibody in the body owes its long life to the neonatal Fc receptor, FcRn - a receptor that grabs IgG inside cells before it can be degraded and ferries it back out into circulation, letting IgG persist for weeks instead of hours. That same recycling machinery keeps pathogenic autoantibodies alive in diseases like myasthenia gravis, where antibodies against the acetylcholine receptor jam signaling at the neuromuscular junction. Efgartigimod exploits the system directly: it is the isolated Fc fragment of a human IgG1 antibody, engineered with argenx's ABDEG (antibodies that enhance IgG degradation) mutations so that it clamps onto FcRn far more tightly than ordinary IgG and, crucially, holds on even at the neutral pH of the cell surface where natural IgG would let go. With FcRn occupied by the drug, circulating IgG can no longer be rescued, so it is routed to the lysosome and destroyed. The effect is a fast, deep, and reversible reduction in total IgG - and therefore in the disease-causing autoantibodies - while leaving IgM, IgA, complement, and albumin untouched, which distinguishes it from broad immunosuppression, plasma exchange, or high-dose IVIg. This selectivity is the whole appeal of the FcRn class. Older approaches to antibody-mediated disease either suppressed the immune system wholesale (steroids, broad immunosuppressants) or physically removed antibodies (plasmapheresis); efgartigimod instead tunes down the IgG pool pharmacologically, on a schedule, and lets it recover between cycles. argenx developed it as ARGX-113 and won the first-ever FcRn-blocker approval in December 2021, when the FDA cleared intravenous Vyvgart for AChR-antibody-positive generalized myasthenia gravis based on ADAPT, a Phase 3 trial in which about 68% of treated patients were MG-ADL responders versus roughly 30% on placebo, with benefits appearing within one to two weeks of a dosing cycle. The company then extended the franchise through formulation and indication: Vyvgart Hytrulo, a subcutaneous co-formulation with Halozyme's recombinant human hyaluronidase PH20 that allows a 30-to-90-second injection instead of an hour-long infusion, was approved for gMG in 2023 and, in June 2024, became the first FcRn blocker approved for CIDP on the basis of the ADHERE study, which used a randomized-withdrawal design to show a sharply lower relapse risk in responders. In April 2025 a prefilled-syringe version enabled at-home self-injection. The most recent milestone came on May 8, 2026, when the FDA broadened the gMG indication to cover all antibody serotypes, including the roughly one in ten gMG patients who are seronegative (no detectable AChR, MuSK, or LRP4 antibodies), after the Phase 3 ADAPT SERON trial showed consistent MG-ADL improvement across MuSK-positive, LRP4-positive, and triple-seronegative patients - making efgartigimod the first and only treatment cleared for every gMG subtype. Because the mechanism is disease-agnostic - it works wherever IgG autoantibodies drive pathology - efgartigimod is in trials across a wide autoimmune landscape, including primary immune thrombocytopenia (the ADVANCE program), idiopathic inflammatory myopathy (myositis), Sjogren's disease, bullous pemphigoid, and lupus nephritis, positioning FcRn blockade as a platform rather than a single-disease drug.
Regulatory Status
Efgartigimod alfa is an FDA-approved prescription biologic marketed by argenx as Vyvgart (intravenous efgartigimod alfa-fcab) and Vyvgart Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc, co-formulated with recombinant human hyaluronidase PH20). It is not a dietary supplement, a compounded product, or a research chemical, and it must be prescribed and administered under medical supervision; any 'efgartigimod' or 'ARGX-113' offered by a research-chemical vendor is unverified and should not be used. Approved U.S. indications: generalized myasthenia gravis in adults (initially AChR-antibody-positive in December 2021; expanded to all serotypes including seronegative patients on May 8, 2026) and chronic inflammatory demyelinating polyneuropathy (June 2024, subcutaneous). It is also approved in the EU, Japan, and other markets for gMG. Identifiers: CAS 1821402-21-4; DrugBank DB15270; UNII 961YV2O515; ATC L04AL01. Molecular formula approximately C2310H3554N602O692S14, molar mass ~51.3 kDa. Investigational for primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis - uses that are not yet approved.
Why Researchers Study It
Efgartigimod is the proof of concept for an entire drug class - the FcRn antagonists - and the first to reach the market. It matters to researchers because it validated a fundamentally new way to treat antibody-mediated autoimmune disease: instead of suppressing the immune system broadly or filtering antibodies out of the blood mechanically, it pharmacologically lowers the circulating IgG pool by blocking the receptor that recycles it, achieving a fast, deep, selective, and reversible reduction in pathogenic autoantibodies. That selectivity - IgG falls while IgM, IgA, complement, and albumin are spared - makes it a clean tool for asking which diseases are truly driven by IgG autoantibodies, and its rapid onset (benefit within one to two weeks of a cycle) and cyclic dosing make it a model for titratable immunomodulation. Because the mechanism is disease-agnostic, efgartigimod is studied as a platform across myasthenia gravis, CIDP, immune thrombocytopenia, myositis, pemphigoid, and other conditions, and as a benchmark against which newer FcRn blockers (rozanolixizumab, nipocalimab, batoclimab) are measured. It is also a case study in antibody engineering, showing how isolating and mutating a single Fc fragment (the ABDEG modification) can convert a passive structural motif into an active therapeutic.
Proposed Mechanisms
- Engineered fragment of the human IgG1 constant (Fc) region - the exact portion of an antibody that binds the neonatal Fc receptor (FcRn) - rather than a small synthetic peptide, produced as a recombinant biologic
- Modified with argenx's ABDEG (antibodies that enhance IgG degradation) technology so it binds FcRn with substantially higher affinity than natural IgG at both acidic (endosomal) and neutral (cell-surface) pH, allowing it to occupy the receptor where ordinary IgG would release
- By saturating FcRn, it blocks FcRn-mediated recycling of endogenous IgG; IgG that would normally be rescued from the endosome is instead routed to the lysosome and degraded, lowering total circulating IgG by roughly 60-70% within weeks
- Selectively reduces all IgG subclasses - including the pathogenic autoantibodies that drive diseases like myasthenia gravis, CIDP, and immune thrombocytopenia - without lowering IgM, IgA, complement, or albumin, distinguishing it from broad immunosuppression, plasma exchange, and IVIg
- In the subcutaneous Vyvgart Hytrulo co-formulation, recombinant human hyaluronidase PH20 (rHuPH20) transiently depolymerizes hyaluronan in the subcutaneous space, allowing a large-volume dose to be delivered as a 30-to-90-second injection instead of an intravenous infusion
- Effect is reversible: after a dosing cycle FcRn function and IgG levels recover, enabling cyclic 'reduce and recover' dosing rather than continuous depletion
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 3 (ADAPT, NCT03669588) - randomized, double-blind, placebo-controlled | 167 adults with generalized myasthenia gravis (AChR-antibody-positive and seronegative); intravenous efgartigimod 10 mg/kg in cycles versus placebo | In the AChR-antibody-positive population, 67.7% of efgartigimod-treated patients were MG-ADL responders versus 29.7% on placebo, with clinically meaningful improvement appearing within 1-2 weeks of a cycle. Basis for the first-ever FcRn-blocker approval (Vyvgart, December 2021). Published in Lancet Neurology, 2021 | Source |
| Phase 2 (ADHERE, NCT04281472) - randomized-withdrawal, placebo-controlled | Adults with chronic inflammatory demyelinating polyneuropathy (CIDP); subcutaneous efgartigimod PH20 (Vyvgart Hytrulo), responders re-randomized to drug or placebo | Efgartigimod produced a markedly lower risk of clinical relapse versus placebo in the randomized-withdrawal period, supporting the June 2024 approval as the first FcRn blocker for CIDP | Source |
| Phase 3 (ADAPT SERON, NCT06298552) - randomized, double-blind, placebo-controlled | 119 adults with AChR-antibody-negative (seronegative) generalized myasthenia gravis, including MuSK-positive, LRP4-positive, and triple-seronegative cohorts; subcutaneous efgartigimod over a 5-week treatment period | Mean MG-ADL improvement of about 3.35 points at week 4, with consistent MG-ADL and QMG benefit across all seronegative cohorts. Basis for the May 8, 2026 FDA expansion of the gMG label to all serotypes, making efgartigimod the first and only treatment approved for every gMG antibody subtype | Source |
| Phase 3 (ADVANCE program, incl. SC study NCT04687072) - randomized, placebo-controlled | Adults with primary immune thrombocytopenia (ITP); intravenous and subcutaneous efgartigimod versus placebo, evaluating durable platelet response | Investigational: FcRn blockade lowers anti-platelet IgG and has shown platelet responses in ITP trials; ITP is not yet an approved indication, and this represents an extension of the platform beyond neuromuscular disease | Source |
Commonly Discussed Benefits
Researching Efgartigimod? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Efgartigimod is a prescription biologic that must be administered under medical supervision (intravenous Vyvgart or subcutaneous Vyvgart Hytrulo); it is not a supplement or self-sourced research chemical, and any product sold as 'efgartigimod' or 'ARGX-113' outside a pharmacy or clinical trial is unverified and unsafe
- By design it lowers total IgG by roughly 60-70%, which can increase susceptibility to infections, particularly respiratory and urinary tract infections; the most common adverse events in trials were infections, headache, and (for the subcutaneous form) injection-site reactions
- The long-term consequences of repeated, sustained IgG reduction - including cumulative infection risk and response to vaccines - are still being characterized, and live vaccines are generally avoided during treatment
- It selectively reduces IgG but does not address non-IgG disease mechanisms; it is not effective for autoimmune conditions driven by IgM, T cells, or complement independent of IgG, and is not an immunosuppressant in the traditional sense
- Approved uses are specific (generalized myasthenia gravis across all serotypes, and CIDP); use in immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis remains investigational and unproven
- It is a targeted therapy for antibody-mediated disease and has no established role in performance enhancement, anti-aging, or general wellness - contexts in which the peptide/biologic label is sometimes misapplied
Comparisons
See how Efgartigimod compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG (all serotypes, including seronegative) - argenx, May 2026 PubMed
- [2] Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis (ADAPT SERON) - NeurologyLive PubMed
- [3] FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - NeurologyLive PubMed
- [4] Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases (mechanism, ABDEG technology) - The Antibody Society PubMed
- [5] Efgartigimod alfa (identifiers, mechanism of action, indications) - DrugBank DB15270 PubMed
- [6] Vyvgart (efgartigimod alfa) FDA Approval History - Drugs.com PubMed
- [7] Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) FDA Approval History - Drugs.com PubMed
Keep researching in the app
- Log Efgartigimod to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Larazotide
Medium EvidenceA synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure.
Zilucoplan
High EvidenceA self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis.
Efzofitimod
Medium EvidenceA first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease.
Pegcetacoplan
High EvidenceA PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market.
Sotatercept
High EvidenceSotatercept (Winrevair, sotatercept-csrk) is Merck's first-in-class activin signaling inhibitor - a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap for activin A, activin B, GDF-8 (myostatin) and GDF-11. It is FDA-approved for adults with pulmonary arterial hypertension (PAH), where it improved 6-minute walk distance by 40.8 meters in the Phase 3 STELLAR trial and, in the Phase 3 ZENITH trial in high-risk patients, cut the composite risk of death, lung transplantation and PAH hospitalization by 76%. An expanded U.S. label reflecting ZENITH was approved on October 27, 2025.
Nipocalimab
High EvidenceNipocalimab (brand name Imaavy, development code M281) is a fully human, aglycosylated, 'effectorless' IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Johnson & Johnson (Janssen). Like efgartigimod it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by occupying FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 65-75% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, nipocalimab is a full-length monoclonal antibody engineered to be aglycosylated and effectorless (it does not trigger ADCC or complement-dependent cytotoxicity), and it is dosed as a maintenance intravenous infusion for continuous IgG suppression rather than in short cycles. The FDA approved Imaavy on April 30, 2025 for generalized myasthenia gravis (gMG) in anti-AChR-antibody-positive and anti-MuSK-antibody-positive patients aged 12 and older - making it the first FcRn blocker approved for adolescents and the first to explicitly cover MuSK-positive disease - on the strength of the Phase 3 Vivacity-MG3 trial. It has since generated positive data across a striking breadth of IgG-mediated conditions: Sjogren's disease (Phase 2 DAHLIAS), rheumatoid arthritis, warm autoimmune hemolytic anemia (wAIHA), and - uniquely among FcRn blockers - maternal-fetal alloimmune disease, where it is being developed to treat hemolytic disease of the fetus and newborn (HDFN) by crossing the placenta to protect the fetus. In April 2026 the FDA granted Priority Review to nipocalimab for wAIHA, positioning it as a potential first approved therapy for that condition.
Rozanolixizumab
High EvidenceRozanolixizumab (brand name Rystiggo, development code UCB7665) is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by UCB. Like efgartigimod and nipocalimab it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by binding FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 70-80% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, rozanolixizumab is a full-length humanized antibody, and unlike nipocalimab's intravenous infusion it is given as a rapid subcutaneous infusion (including via an on-body delivery device), typically in weekly cycles that are repeated based on clinical response rather than continuously. The FDA approved Rystiggo on June 27, 2023 for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine-receptor (AChR) antibody-positive or anti-muscle-specific-tyrosine-kinase (MuSK) antibody-positive - making it the first therapy ever approved to treat both of those gMG subtypes - on the strength of the Phase 3 MycarinG trial. It has since been studied across other IgG-mediated diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), where it did not show meaningful benefit and was not advanced to Phase 3, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), primary immune thrombocytopenia (ITP), and other autoantibody conditions where development continues. The European Medicines Agency approved rozanolixizumab in January 2024 and the UK MHRA in March 2024.
Batoclimab
High EvidenceBatoclimab (development codes IMVT-1401, RVT-1401, HBM9161, HL161) is an investigational, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Immunovant/Roivant (U.S. and Canada) and Harbour BioMed (Greater China) under license from HanAll Biopharma. It is not a small synthetic peptide but a full-length antibody given as a low-volume subcutaneous injection that patients can self-administer at home. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab, it lowers circulating IgG - including pathogenic autoantibodies - but it is best known for two things the others are not: it is the FcRn blocker that generated positive Phase 3 myasthenia gravis data yet was deliberately NOT filed for U.S. approval, and it is the one whose FcRn-mediated albumin recycling blockade produces a distinctive on-target signal of lowered serum albumin and raised LDL cholesterol - the exact liability that drove its makers to a re-engineered successor, IMVT-1402.
IMVT-1402
Medium EvidenceIMVT-1402 (international nonproprietary name imeroprubart; originally HL161ANS) is Immunovant/Roivant's investigational, next-generation, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn). It is a re-engineered successor to batoclimab, built to keep batoclimab's deep IgG-lowering while removing that molecule's defining liability: because FcRn recycles serum albumin as well as IgG, first-generation FcRn blockers reproducibly lowered albumin and raised LDL cholesterol, and IMVT-1402 was specifically designed to spare albumin and lipids. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab it lowers circulating IgG - including pathogenic autoantibodies - but it is distinguished by two things: a low-volume subcutaneous autoinjector for at-home self-administration, and Phase 1 data showing 60-80% IgG reduction with no albumin drop and no LDL rise. It is now Immunovant's lead pipeline asset, advancing across roughly six autoimmune indications with potentially registrational Graves' disease and myasthenia gravis readouts expected in 2027.